General Information
89bio MASH 131
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
| Protocol | BIO89-100-131 |
|---|---|
| Identifier | |
| UID | 6956f42a-b847-4f8c-b64f-49be09f08b97 |
| Status | Enrollment |
| Phase | 3 |
| Category | MASH / Adult |
| Launch Year | 0 |
| NCT Number | - |
| Created | 2024-01-24 13:27 |
| Last Updated | 2024-06-20 19:49 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | 2024-06-20 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2024-04-23 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | No | |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Gomez, Kathie | KGomez | No |
| Coordinator | Andujo, Darlene | DCano | No |
| Regulatory | Romero, Araselly | ARomero | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | 89Bio Ltd. |
|---|---|
| Division | 89Bio Ltd. |
| Team | 89Biob Ltd. |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Medpace, Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | LimeGreen |
| Currency | - |
